
Customize View

Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
There are no recently disclosed strategic alliances listed

Prior and Not Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
Carna Biosciences, Inc. (TSE:4572)
Inixium Inc.
Life Sciences Tools and Services
Carna Biosciences, Inc. (TSE:4572) - Form 
Business Description: Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
PCAS SA (ENXTPA:PCA)
BoroChem
Life Sciences Tools and Services
PCAS SA (ENXTPA:PCA) 2010 Form 
Business Description: PCAS SA develops and produces complex molecules for life sciences and technologies. The company was founded in 1962 and is headquartered in Longjumeau, France. PCAS SA is a subsidiary of Seqens SAS
*denotes proprietary relationship